From a technical perspective, Boston Scientific (BSX) is looking like an interesting pick, as it just reached a key level of support. BSX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Boston Scientific Corporation (NYSE:BSX ) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Jonathan Monson - Executive VP & CFO Ken Stein - Senior VP & Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Joanne Wuensch - Citigroup Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Michael Polark - Wolfe Research, LLC Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Christopher Pasquale - Nephron Research LLC Pito Chickering - Deutsche Bank AG, Research Division Presentation Operator Good morning, and welcome to the Boston Scientific Third Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.63 per share a year ago.
There are two types of Halloween people: those who like jump scares and those who don't. But even if you're a fan of haunted hayrides and movies like The Conjuring, you probably don't want to ever get a jump scare from your portfolio, which is why so many investors use diversified index funds with the bulk of their wealth.
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Medical device maker Boston Scientific said on Friday it will buy privately-held Nalu Medical for a cash payment of about $533 million, expanding its portfolio to address chronic pain.
Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthcare market is expected to reach $504B by 2032, driven by an aging population, medical data explosion, job shortages, and consumer demand for self-care technology. Healthcare companies are increasingly deploying AI in drug discovery, diagnostics, imagery, robot-assisted surgery, and hospital administration.
The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.